ArticleMolecular and clinical oncology2017
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Immunotherapy in Bellini Duct Carcinoma: A Systematic Review.Oncology research · 2026Pooled it
- Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan.BMC cancer · 2025Article
- Rare Case of Collecting Duct Carcinoma With Complete Response to Nivolumab.Case reports in oncological medicine · 2025Article
- Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.Human vaccines & immunotherapeutics · 2023Review
- Article
- A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney.Asian journal of urology · 2023Article
- Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases.IJU case reports · 2022Article
- Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.Journal of medical case reports · 2022Article
- Article
- Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease.Frontiers in oncology · 2022Review
- Collecting duct renal cell carcinoma: a single centre series and review of the literature.Central European journal of urology · 2022Article
- Review
- Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma.Cancers · 2021Article
- Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma.Case reports in urology · 2021Article
- Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication.Cancers · 2020Article
- Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.International cancer conference journal · 2020Article
- Rechallenge of carboplatin-gemcitabine based chemotherapy for rapidly progressing metastatic collecting duct carcinoma of the kidney leading to a delayed and durable complete response: A case report.Oncology letters · 2019Article
- Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.Medicine · 2018Article
- Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities.Research and reports in urology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors present a case report of collecting duct carcinoma (CDC) that responded to nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following the failure of systemic treatment with chemotherapy and targeted therapy. The patient underwent right radical nephrectomy and segmentectomy of the lung following chemotherapy. Fifteen months following the first surgery, segmentectomy and subsequent second-line chemotherapy were performed for recurrence in the lung. Targeted therapy with temsirolimus for recurrence of the lung and lymph node metastases was ultimately used for 30 months. However, the temsirolimus treatment failed to suppress the growth of metastatic lesions. Nivolumab resulted in complete response of the lung metastasis, and it stabilized the lymph node metastasis. PD-L1 was highly expressed in both primary tumor and the metastatic regions. Therapy with nivolumab is ongoing. These findings suggest that treatment with nivolumab may be considered for metastatic and treatment-failure CDC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.